Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aripiprazole/sertraline - Otsuka Pharmaceutical

Drug Profile

Aripiprazole/sertraline - Otsuka Pharmaceutical

Alternative Names: ASC-01; Sertraline/aripiprazole

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Amines; Antidepressants; Chlorobenzenes; Mood stabilisers; Naphthalenes; Piperazines; Quinolines; Small molecules
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D2 receptor agonists; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Submission Withdrawal Major depressive disorder

Most Recent Events

  • 30 Sep 2018 Discontinued - Phase-III for Major depressive disorder in Taiwan, South Korea, Malaysia, Australia (PO) (Otsuka Pharmaceutical pipeline, September 2018)
  • 30 Sep 2018 Regulatory submission withdrawn for Major depressive disorder in Japan (PO) (Otsuka Pharmaceutical pipeline, September 2018)
  • 27 Aug 2018 Otsuka Pharmaceutical completes a phase I bioequivalence trial in healthy volunteers in Japan (PO) (JapicCTI173774) (NCT03342963)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top